Download DNB 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 2 Question Paper

Download Diplomate in National Board (DNB) 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 2 Previous Question Papers

FINAL EXAM
JUNE 2019
Time: 3 hours
NATIONAL BOARD OF EXAMINATIONS
MEDICAL ONCOLOGY
PAPER-Il
Max. Marksz100
Important Instructions:
. Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legib/y.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/f/owcharts wherever appropriate.
Write short notes on:
1 . a)
b)
C)
2. a)
b)
C)
3. a)
b)
c)
4. a)
b)
C)
5. a)
b)
C)
6. a)
b)
0)
POSSESSION/USE OF CELL PHONES 0R AN Y S UCH ELECTRONIC GADGETS IS NOTPERMITTED INSIDE THE EXAMINA TION HALL.
Causes of malignant spinal cord compression (MSCC).
Grading the MSCC.
Management of MSCC.
Gene expression profile.
What are the tests available for breast cancer gene
expression profile?
Use of gene expression profile results in breast cancer
management.
Staging of non-small cell lung cancer (NSCLC)
according to 8?? Edition Lung Cancer Stage
Classification.
Role of mutation analysis in treatment of NSCLC.
Consolidation treatment after definitive concurrent
chemo-radiation in stage III NSCLC.
Role of PET CT scan in lymphomas.
Limitations of PET CT use in clinical practice.
PET response adopted treatment in Hodgkin?s
lymphoma.
WHO Classification of neuroendocrine tumours of
pancreas.
Management of advanced pancreatic neuroendocrine
tumours.
Peptide receptor radiotherapy.
Gleason grading in adenocarcinoma prostate.
Role of PSA in screening and follow up of prostate
canceL
Enumerate anti-androgen therapies in carcinoma
prostate.
-1.
MED ONCO/J/19/17/II
3+3+4
2+4+4
4+3+3
4+3+3
3+4+3
3+3+4
P.T.O.

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
JUNE 2019
MEDICAL ONCOLOGY
PAPER-II
7. a) Role of cytoreductive nephrectomy in metastatic renal 3+4+3
cell carcinoma.
b) Role of adjuvant treatment in clear cell renal cell
carcinoma.
0) Risk scoring systems and their use in metastatic renal
cell carcinoma.
8. a) Explain the methodology of Real time polymerase chain 3+4+3
reaction (RT PCR).
b) Monitoring of response in CML treatment
0) Criteria for accelerated phase and blast crisis in CML.
9. a) Etiological factors of Hepatocellular Carcinoma (HCC). 3+4+3
b) Diagnosis and staging of HCC.
0) Indications of allogenic liver transplantation in HCC.
10. a) Enumerate various types of neck dissections in 3+4+3
squamous cell carcinoma of head and neck.
b) Role of neo-adjuvant chemotherapy in oro-pharyngeal
canceL
0) Rehabilitation after laryngectomy.
***************
-2.
POSSESSION/USE OF CELL PHONES 0R AN Y S UCH ELECTRONIC GADGETS IS NOTPERMITTED INSIDE THE EXAMINA TION HALL.